9 completed, 2 recruiting, 1 terminated, 1 withdrawn. 5 Phase 1, 5 Phase 2, 1 Early Phase 1, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 3, Recruiting 1, Terminated 1 |
| Phase 2 | 5 | Completed 3, Recruiting 1, Terminated 1 |
| Early Phase 1 | 1 | Completed 1 |
| Not applicable | 1 | Completed 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Lymphocytic Leukemia: new trials by email Literature Review of Lymphocytic Leukemia trials Research Report on Lymphocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD Mosunetuzumab - Lymphocytic Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2026-07-09 | 2026-08-12 |
| A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL MS-553 - Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Terminated | Shenzhen MingSight Relin Pharmaceuticals Co., Ltd. | 13 | 2022-04-28 | 2024-07-18 |
| Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy BMS-986345, Duvelisib - Non Hodgkin Lymphoma, Hodgkin Lymphoma | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 14 | 2021-11-18 | 2025-12-04 |
| A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL. NeoVax, Cyclophosphamide, Pembrolizumab - Lymphocytic Leukemia | Phase 1 | Recruiting | Dana-Farber Cancer Institute | 15 | 2021-08-18 | 2026-05-28 |
| Symbenda Post-Marketing Surveillance (PMS) Lymphoma, Non-Hodgkin, Lymphocytic Leukemia | Completed | Eisai Korea Inc. | 84 | 2018-07-04 | 2021-01-26 | |
| A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Ibrutinib - Lymphocytic Leukemia | Phase 1 | Completed | Janssen Pharmaceutical K.K. | 8 | 2015-07-03 | 2019-08-14 |
| Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients Lirilumab, Rituximab - Leukemia, Chronic Lymphocytic Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 7 | 2015-06-23 | 2020-05-28 |
| Effect of Product Related Factors on Platelet Concentrate Transfusion Response in Patients With Hematologic Malignacies Platelet concentrate transfusion - Lymphoma, Multiple Myeloma | Completed | Etablissement Français du Sang | 1101 | 2015-01-01 | 2017-10-02 | |
| Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma alemtuzumab, everolimus - Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Mayo Clinic | 28 | 2009-07-01 | 2017-09-26 |
| Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab Lenalidomide, Rituximab - Lymphocytic Leukemia, Mantle Cell Lymphoma | Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 29 | 2007-10-01 | 2015-09-17 |
| This Study is Being Performed to Evaluate the Effect of Genasense on the Efficacy and the Safety of Rituximab/Fludarabine Combination Treatment in Previously Untreated Subjects With Chronic Lymphocyctic Leukemia(CLL) Genasense® (, oblimersen sodium G3139) - Lymphocytic Leukemia | Phase 3 | Withdrawn | Genta Incorporated | 2006-06-01 | 2008-02-11 | |
| Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies Stem cell transplantation - Hodgkin Lymphoma, Lymphocytic Leukemia | Early Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2001-03-14 | 2019-12-16 |
| Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies fludarabine/busulfan, fludarabine/ melphalan, ATG - Acute Myeloid Leukemia, Acute Leukemia | Not applicable | Completed | University of Illinois at Chicago | 100 | 2000-02-01 | 2018-11-08 |
Leukemia, Lymphoid (13) · Hodgkin Disease (4) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Leukemia (3) · Lymphoma (3) · Lymphoma, Non-Hodgkin (3) · Multiple Myeloma (3) · Recurrence (2) · Anemia, Aplastic (1) · Blast Crisis (1) · Hematologic Neoplasms (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, Mantle-Cell (1)
Hematologic Diseases (13) · Hemic and Lymphatic Diseases (13) · Immune System Diseases (13) · Immunoproliferative Disorders (13) · Lymphatic Diseases (13) · Lymphoproliferative Disorders (13) · Neoplasms by Histologic Type (13) · Neoplasms (12) · Leukemia (10) · Chronic Disease (4) · Disease Attributes (4) · Leukemia, B-Cell (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Blood Protein Disorders (3)
Rituximab (2) · Alemtuzumab (1) · Azacitidine (1) · Busulfan (1) · Cyclophosphamide (1) · Everolimus (1) · Lenalidomide (1) · Melphalan (1) · Stem Cell Transplantation (1) · duvelisib (1) · fludarabine (1) · fludarabine phosphate (1) · ibrutinib (1) · lirilumab (1) · oblimersen (1)
H. Lee Moffitt Cancer Center and Research Institute (2) · M.D. Anderson Cancer Center (2) · Dana-Farber Cancer Institute (1) · Eisai Korea Inc. (1) · Etablissement Français du Sang (1) · Genta Incorporated (1) · Janssen Pharmaceutical K.K. (1) · Mayo Clinic (1) · National Cancer Institute (NCI) (1) · Shenzhen MingSight Relin Pharmaceuticals Co., Ltd. (1) · University of Illinois at Chicago (1)
United States (8) · China (1) · Japan (1) · South Korea (1)
Clive S. Zent, M.D. (1) · Damiano Rondelli, MD (1) · Hayder Saeed, MD (1) · Inhye Ahn, MD (1) · Javier Pinilla, M.D., PhD. (1) · Jose F. Leis, M.D. (1) · Kai Zhang, MD (1) · Mahesh Swaminathan, MD (1) · Nitin Jain, MBBS (1) · Terry J Fry, M.D. (1)